Caribou Biosciences Q2 net loss narrows to $24.3 million from $54.1 million
Caribou Biosciences reported a second-quarter 2026 net loss of $24.3 million, or $0.24 per share, compared with $54.1 million, or $0.58 per share, a year earlier. The prior-year figure included $21.3 million in non-cash impairment charges, and licensing and other third-party revenue fell to $1.5 million from $2.7 million. The company now expects its cash to fund its current operating plan to the end of 2027, but cash, cash equivalents, and marketable securities declined to $113.8 million as of June 30, 2026, and the company said it is exploring options to fully fund its planned ANTLER-3 trial.
Key points
- Net loss of $24.3 million, or $0.24 per share, for the quarter ended June 30, 2026, versus $54.1 million, or $0.58 per share, a year earlier
- Licensing and other third-party revenue of $1.5 million, down from $2.7 million in the same period of 2025
- Cash, cash equivalents, and marketable securities of $113.8 million at June 30, 2026, down from $142.8 million at December 31, 2025
- Cash now expected to fund the current operating plan to the end of 2027; the company is exploring multiple options to fully fund the ANTLER-3 trial
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.